Biovian in GEN Magazine – A 360-Degree View of AAV Production
Adeno-associated virus (AAV) has emerged as the most flexible and useful vector for gene therapy. With hundreds of gene therapy trials ongoing, safe and efficient production of AAV is absolutely critical.
In this roundtable discussion, four experts from academia and industry, including Magnus Gustafsson from Biovian, met to discuss challenges in refining and scaling up AAV production pipelines to meet the increasing demand for these indispensable viral vector delivery systems.
Magnus Gustafsson: This massive increase in demand is because there are more clinical trials. And that’s because AAV vectors work. We have higher dosing because companies choose systemic delivery over local administration and study larger patient populations. Different applications require vastly different amounts of vector. We need to have something to adjust for that massive difference.